allosteric英标：['æləstɪərɪk]
含义：别构的
发音：['æləstə'ɪərɪk]
用法：用于描述蛋白质结构变化导致其功能改变的现象。
记忆方法：all（全部） + o（看做一个整体） + steric（空间结构） = 所有的空间结构变化都会影响蛋白质的功能。
分别的用法：通常表示在某个特定的时间点或者情况下，两者之间存在一种分离或者不在一起的状态。例如，“他们分别在两个不同的城市工作。”
分别的发音：[ˈviˈni]
希望以上信息对您有帮助。
allosteric物理现象是指蛋白质分子在正常生理条件下存在多种稳定和协调的结构因子，这些因子可以与辅因子或代谢底物相互作用，改变蛋白质的活性，而无需改变蛋白质的天然构象
^[2]^。
Allosteric modulation是指别构调控，是指利用别构效应来改变酶的活性，这种效应通过与酶的底物或辅基相互作用产生，可以显著影响酶的活性。别构效应在生物体的多种代谢过程中扮演重要的角色，是蛋白质功能行使的关键环节。同时，allosteric机制是生物体内一种重要的蛋白质活性调节机制，广泛存在于蛋白质酶、离子通道等生物大分子^[1]^。
Allosteric modulation: A new approach for managing diseases
In recent years, allosteric modulation has emerged as a powerful new approach for drug development. Allosteric modulation refers to the modulation of a protein's activity by binding to a site on the protein other than its active site. This approach has the potential to address many diseases that have been difficult to treat, including neurodegenerative diseases, cardiovascular diseases, and infectious diseases.
One of the key advantages of allosteric modulation is that it can be targeted to specific proteins, allowing for greater specificity and fewer side effects. By targeting proteins that are key regulators in disease processes, allosteric modulators can have a more targeted and effective approach to treatment.
Moreover, allosteric modulation can be used in combination with other therapeutic strategies. For example, allosteric modulators can be used to enhance the effects of existing drugs or to provide additional therapeutic benefit in combination with other therapies. This approach can lead to more effective treatment strategies and reduce the need for multiple drugs, which can increase the risk of side effects and reduce patient compliance.
However, despite these potential advantages, the development of allosteric modulators is not without challenges. One of the main challenges is the identification of suitable allosteric binding sites on proteins. This can be a time-consuming and costly process, requiring extensive research and screening of potential ligands.
Another challenge is the optimization of allosteric modulators to achieve optimal efficacy and safety. This requires a deep understanding of the protein-ligand interactions and the ability to modify ligands to improve their binding affinity and specificity.
Finally, allosteric modulation may not be suitable for all diseases and patients. Some diseases may require targeting of critical proteins that are not amenable to allosteric modulation, or patients may have conditions that make them vulnerable to side effects from allosteric modulators.
In conclusion, allosteric modulation represents a promising new approach for drug development that has the potential to address many difficult-to-treat diseases. With further research and development, allosteric modulators may become a valuable tool in the fight against disease. However, it is important to recognize the challenges involved in developing these agents and to ensure that they are used appropriately and safely.